Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamlanoflast in Amyotrophic Lateral Sclerosis
NCT07396818Phase 2Not yet recruiting
- Sponsor
- Inflammasome Therapeutics
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of kamlanoflast in amyotrophic lateral sclerosis (ALS), sponsored by Inflammasome Therapeutics. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
kamlanoflast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07396818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396818.